Results 81 to 90 of about 13,683 (246)

Fatigue Assessment Using FACIT-F Scale in Spondyloarthropathy Patients and its Correlation with BASDAI and BASFI Scores

Journal of the College of Physicians and Surgeons Pakistan
To measure fatigue in axial spondyloarthropathy patients and find its correlation with the disease activity measures.Cross-sectional, descriptive study. Place and Duration of the Study: Rheumatology Unit, Federal Government Polyclinic Hospital, from November 2021 to May 2022.This study included 45 patients fulfilling the ASAS criteria for ...
Sarah Azam Shah, Taqdees Khaliq, Saad Saleem   +2 more
openalex   +4 more sources

Cardiovascular training improves fitness in patients with ankylosing spondylitis [PDF]

, 2013
Objective: Several studies suggest that patients with ankylosing spondylitis (AS) have an increased risk of cardiovascular disease. This study aimed to evaluate the effects of a 12-week individually heart rate-monitored, moderately intensive ...
ACSM, ACSM, Ainsworth, Altman, Balady, Braun, Braun, Calin, Dagfinrud, Dagfinrud, Dagfinrud, Daltroy, den Ende, den Ende, Erbs, Garrett, Gore, Graf, Graham, Grant, Hambrecht, Han, Heijde, Hootman, Jenkinson, Kabat-Zinn, Kang, Lautermann, Linden, Lollgen, Lukas, Mader, Minor, Neuberger, Nocon, Pedersen, Pentecost, Peters, Pincus, Richardson, Schiffer, Sjoquist, Sjoquist, Swartz, Talbot, Trost, Ward, Willson   +47 more
core   +1 more source

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang, Jingya Gao, Furong Li, Luyuan Li, Yue Xiao, Hongxiang Hu, Xiya Peng, Min Yang, Dan Hao, Wei Yan, Dengmei Xia, Wei Li   +11 more
wiley   +1 more source

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. [PDF]

, 2017
Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA).
Adrian Ciurea, Almut Scherer, Burkhard Möller, Giorgio Tamborrini, Jürg Bernhard, Lukas M. Wildi, Michael J. Nissen, Monika Hebeisen, on behalf of the Rheumatologists of the Swiss Clinical Quality Management Program, Pascal Zufferey, Pascale Exer, Raphael Micheroli   +11 more
core   +5 more sources

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy

International Journal of Dermatology, EarlyView.
ABSTRACT Background Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness in PsA patients treated in dermatologic settings.
Giacomo Caldarola, Annunziata Dattola, Nicoletta Bernardini, Veronica Blundo, Elena Campione, Eleonora De Luca, Domenico Giordano, Alessandro Giunta, Gaia Moretta, Diego Orsini, Gianluca Pagnanelli, Antonio Richetta, Andrea Picchianti Diamanti   +12 more
wiley   +1 more source

Patient‐reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID‐19 Pandemic

ACR Open Rheumatology, 2020
Objective Response to the coronavirus disease 2019 (COVID‐19) pandemic has resulted in shelter‐in‐place orders and major changes to individuals’ daily lives.
Jean W. Liew, Maria Castillo, Ethan Zaccagnino, Patricia Katz, Nigil Haroon, Lianne S. Gensler   +5 more
doaj   +1 more source

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [PDF]

, 2014
Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. Methods: In
Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., Chattapadhyay, C., Chudzik, D., Claudepierre, P., Cooper, R., Dooley, L. T., Doyle, M. K., Drescher, E., Dutz, J., Edwards, C., El-Kadi, H., Elewski, B., Erlacher, L., Flipo, R., Fretzin, S., George, E., Gladstein, G., Gottlieb, A. B., Griffin, R., Grisanti, M., Guenther, L., Gulliver, W., Hobbs, K., Huang, E., Ilivanova, E., Jeka, S., Kavanaugh, A., Khraishi, M., Kokhan, M., Korman, N., Kunynetz, R., Leonardi, C., Lessard, C., Li, S., Lindquist, U., Martin, A., Matheson, R., McInnes, I.B., Mendelsohn, A. M., Murphy, F., Nasonov, E., Palmer, W., Papp, K., Perate, M., Puig, L., Rahman, P., Rech, J., Rell-Bakalarska, M., Rich, P., Ritchlin, C., Rosen, C., Rudin, A., Ruppert-Roth, A., Scheinecker, C., Seigel, S., Shaikh, S., Sheeran, T., Shen, Y.-K., Shergy, W., Siegel, E., Sierakowski, S., Sofen, H., Szanto, S., Tahir, H., Telegdy, E., Toth, D., Walker, D., Wang, Y., Whitman, M., Wilson, A., Witt, M., Wollenhaupt, J., Zoschke, D., Zubrzycka, A.   +77 more
core   +1 more source

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort

Arthritis Care &Research, Volume 77, Issue 8, Page 1007-1013, August 2025.
Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara, Kathleen Bush, M. Elaine Husni, Soumya M. Reddy, Jose U. Scher, Ethan Craig, Joelle Koplin, Jessica A. Walsh, Alexis Ogdie   +8 more
wiley   +1 more source

Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian Ankylosing Spondylitis Patients [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Ankylosing Spondylitis Disease Activity Score (ASDAS) is a complex score for monitoring disease activity in Ankylosing Spondylitis (AS). Aim: To develop a simplified version of the ASDAS.
NAGMA BANSAL, LALIT DUGGAL, NEERAJ JAIN
doaj   +1 more source

Bone formation rather than inflammation reflects Ankylosing Spondylitis activity on PET-CT: a pilot study [PDF]

, 2012
INTRODUCTION: Positron Emission Tomography - Computer Tomography (PET-CT) is an interesting imaging technique to visualize Ankylosing Spondylitis (AS) activity using specific PET tracers.
Boellaard, R., Bruijnen, S.T.G., Denderen, J.C. van, Dijkmans, B.A.C., Hoekstra, O.S., Horst-Bruinsma, I.E. van der, Klein, J.P., Laken, J. van der, Voskuyl, A.E., Weijden, M.A.C. van der   +9 more
core   +2 more sources